Tagged with AMR

Switzerland David Veitch, the CEO of Basilea Pharmaceutica, shares his insights into the company’s strategic vision to become a global leader in the antifungal and antibacterial space. Veitch discusses the unique challenges faced by companies navigating the anti-infectives space, the importance of public funding from partnerships with governmental organizations like BARDA,…

China Yoshitaka Koketsu explains Sumitomo Pharma Group’s positioning in the China market as a relatively recent market entrant with a six-product portfolio but with plentiful opportunities for further growth, particularly in combating infectious diseases and antimicrobial resistance (AMR). Koketsu outlines how the company is well-aligned with China’s regulatory changes, and how…

Europe As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for the coming year, including the lessons to be taken from the pandemic response, why antimicrobial resistance must not be neglected,…

Global Antimicrobial resistance (AMR), or the resistance of pathogens to antibiotics, antivirals, antifungals and antiparasitics has been declared by the World Health Organization (WHO) as one of the top 10 global public health threats and was associated with the death of some 5 million people in 2019. The latest WHO report…

Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it.   Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…

Global In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status of the biosimilars industry, the differences between the European and US markets, the advantages of being part of a large science-based innovator like Novartis, and why competition in biosimilars will…

Sweden Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been a pioneer in the field, and Blanck believes that Sweden is an excellent test market for various incentive models that,…

Turkey Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across MEA. Moreover, he comments on the future of antibiotics as the scientific community warns about antimicrobial resistance, the pandemic’s impact…

Switzerland In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s…

Europe On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of ensuring that “patients have access to innovative and affordable medicines” and “to support the competitiveness, innovative capacity and sustainability of the EU’s pharmaceutical industry”.   This Pharmaceutical Strategy for Europe is seen…

Europe On 25 November, the European Commission adopted a new strategy meant to, among others, allow Europe to cover its pharmaceutical needs, including in times of crisis, through robust supply chains. The strategy also contains a flagship actions to help curb the rise of antimicrobial resistance. Rex Clements, CEO of Centrient…

Europe Dr Pierre Meulien, executive director of the Innovative Medicines Initiative (IMI), the world’s largest life science public-private partnership between the European Union and the European pharmaceutical industry, shares the incredible work IMI has been doing through the COVID-19 pandemic, along with the critical importance of public-private partnerships for areas like…